Last updated on August 2018

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension


Brief description of study

The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

Detailed Study Description

This Bridging Extension is to determine if intravenous CD101 is safe [Day 45- 52 for subjects with candidemia only, or Day 52- 59 for subjects with invasive candidiasis with or without candidemia] and effective [Day 14 ( 1 day)] in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

Clinical Study Identifier: NCT02734862

Contact Investigators or Research Sites near you

Start Over

Augusta University

Augusta, GA United States
  Connect »

Harper University Hospital

Detroit, MI United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

William Beaumont Hospital

Royal Oak, MI United States
  Connect »

Mercury Street Medical

Butte, MT United States
  Connect »

Albany Medical Center

Albany, NY United States
  Connect »

Erasme Hospital

Brussels, Belgium
  Connect »

Kuban State Medical University

Krasnodar, Russian Federation
  Connect »

Territorial Clinical Hospital

Krasnoyarsk, Russian Federation
  Connect »

Mariinskaya City Hospital

Saint Petersburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.